---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-023174"
form_type: "8-K"
ticker: null
cik: "0000786947"
company_name: "ACURA PHARMACEUTICALS, INC"
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:51:16.560204+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Acura Pharma gets $250K loan from related party AD Pharma; total debt $5.17M due March 31, 2024

## Summary
- Received $250,000 loan from AD Pharma (65% owner), increasing total debt to $5,169,279 at 5.25% interest, due March 31, 2024.
- Proceeds fund operations only through mid-March; company warns it may need additional financing by March-end to avoid scaling back or bankruptcy.
- AD Pharma (controlled by Mr. Schutte) directly owns ~65% of Acura's common stock; Mr. Schutte personally owns ~13%.
- If no additional financing by end of March, company may need to terminate operations or seek bankruptcy protection, risking total loss of shareholder value.

## SEC filing metadata
- accession: 0001104659-24-023174
- form_type: 8-K
- cik: 0000786947
- company_name: ACURA PHARMACEUTICALS, INC
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/786947/000110465924023174/0001104659-24-023174-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/786947/000110465924023174/tm246140d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-023174
- JSON: https://secwatch.observer/filing/0001104659-24-023174.json
- Plain text: https://secwatch.observer/filing/0001104659-24-023174.txt

## Key facts
- Debt Financings
  ACURA PHARMACEUTICALS, INC incurred loan of $250,000 loan with Abuse Deterrent Pharma, LLC at 5.25% maturing March 31, 2024.
  - Instrument: loan
  - Principal: $250,000 loan
  - Counterparty: Abuse Deterrent Pharma, LLC
  - Rate: 5.25%
  - Maturity: March 31, 2024
  - Event: incurrence
  source text: On February 14, 2024 we received a $250,000 loan from Abuse Deterrent Pharma, LLC (“AD Pharma”). This loan combined with previous loans made to the Company and with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, now totals $5,169,279, bears interest at 5.25% and matures on March 31, 2024, at which time all principal and interest is due (“Note”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465924023174/0001104659-24-023174-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.